Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017:2017:4853905.
doi: 10.1155/2017/4853905. Epub 2017 Oct 31.

The Influence of Juvenile Graves' Ophthalmopathy on Graves' Disease Course

Jurate Jankauskiene  1 , Dalia Jarusaitiene  1
Affiliations

The Influence of Juvenile Graves' Ophthalmopathy on Graves' Disease Course

Jurate Jankauskiene et al. J Ophthalmol. 2017.

Abstract

Purpose: To investigate juvenile Graves' ophthalmopathy (GO) signs and compare Graves' disease (GD) course in patients with or without GO.

Patients and methods: There were analyzed data (visual acuity, proptosis, palpebral fissure measurements, clinical activity score (CAS), and the course of GD) of 67 children who have been newly diagnosed with GD. 26.9% of patients with GD had signs of ophthalmopathy (GO+), and 73.1% were without ophthalmopathy (GO-).

Results: Upper eyelid retraction (72.3%), proptosis (66.7%), and soft tissue changes (27.8-38.9%) were in GO+ patients. The palpebral fissure, CAS, and proptosis values were greater in the GO+ group than in the GO- group (p < 0.001). GD course in GO+ patients was longer than that in GO- patients (p < 0.001). The duration of the first remission was longer in GO- than in GO+ patients (p < 0.001). The duration of first remission was longer than one year for 61.2% in GO- and 33.3% in GO+ patients (p < 0.02).

Conclusion: The common manifestations of juvenile GO patients were upper eyelid retraction, proptosis, and soft tissue involvement. The study demonstrates that pediatric patients with GO are more likely to have a severe course of autoimmune thyroid disease.

PubMed Disclaimer

References

    1. Krassas G. E., Gogakos A. Thyroid-associated ophthalmopathy in juvenile Graves’ disease–clinical, endocrine and therapeutic aspects. Journal of Pediatric Endocrinology & Metabolism. 2006;19(10):1193–1206. doi: 10.1515/jpem.2006.19.10.1193. - DOI - PubMed
    1. Lee S. H., Lee S. Y., Chung H. R., et al. Remission rate and remission predictors of Graves’ disease in children and adolescents. Korean Journal of Pediatrics. 2009;52(9):1021–1028. doi: 10.3345/kjp.2009.52.9.1021. - DOI
    1. Rivkees S. A. Treatment of hyperthyroidism due to Graves’ disease in children. In: Krassas G. E., Rivkees S. A., Kiess W., editors. Diseases of the Thyroid in Childhood and Adolescence. Basel: Karger; 2007. pp. 169–191. - DOI
    1. Williamson S., Greene S. A. Incidence of thyrotoxicosis in childhood: a national population based study in the UK and Ireland. Clinical Endocrinology. 2010;72(3):358–363. doi: 10.1111/j.1365-2265.2009.03717.x. - DOI - PubMed
    1. Acuna O. M., Athannassaki I., Paysse E. A. Association between thyroid-stimulating immunoglobulin levels and ocular findings in pediatric patients with Graves’ disease. Transactions of the American Ophthalmological Society. 2007;105:146–150. - PMC - PubMed

LinkOut - more resources